APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lipid-lowering Agent

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Lipid-lowering Agent Industry Growth and Trends Forecast to 2032

20 December 2025115 pages

Choose your research edition.

Industry ResearchLipid-lowering Agent Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Lipid-lowering Agent Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Lipid-lowering Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lipid-lowering Agent Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Lipid-lowering Agent Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Lipid-lowering Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Lipid-lowering Agent include Abbott, Teva, SUN Pharma, Novartis, Merck, Pfizer, GlaxoSmithKline, Amgen and Abbvie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Lipid-lowering Agent market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Lipid-lowering Agent market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Lipid-lowering Agent market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Lipid-lowering Agent.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Lipid-lowering Agent market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Lipid-lowering Agent Market by Company

Abbott

Teva

SUN Pharma

Novartis

Merck

Pfizer

GlaxoSmithKline

Amgen

Abbvie

AstraZeneca

Torrent Pharmaceuticals

JX Pharmaceuticals

HanAll BioPharma

Cerenis Therapeutics

Aurobindo Pharma

Lipid-lowering Agent Segment by Type

Acipimox

Fibrates

Niaci

Others

Lipid-lowering Agent Segment by Application

Hospitals

Clinics

Others

Lipid-lowering Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid-lowering Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lipid-lowering Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid-lowering Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Lipid-lowering Agent manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Lipid-lowering Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Acipimox Table 2. Major Company of Fibrates Table 3. Major Company of Niaci Table 4. Major Company of Others Table 5. Global Lipid-lowering Agent Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Lipid-lowering Agent Sales by Type (2021-2026) & (k units) Table 7. Global Lipid-lowering Agent Sales Market Share in Volume by Type (2021-2026) Table 8. Global Lipid-lowering Agent Sales by Type (2021-2026) & (US$ Million) Table 9. Global Lipid-lowering Agent Sales Market Share in Value by Type (2021-2026) Table 10. Global Lipid-lowering Agent Price by Type (2021-2026) & (US$/unit) Table 11. Global Lipid-lowering Agent Sales by Type (2027-2032) & (k units) Table 12. Global Lipid-lowering Agent Sales Market Share in Volume by Type (2027-2032) Table 13. Global Lipid-lowering Agent Sales by Type (2027-2032) & (US$ Million) Table 14. Global Lipid-lowering Agent Sales Market Share in Value by Type (2027-2032) Table 15. Global Lipid-lowering Agent Price by Type (2027-2032) & (US$/unit) Table 16. North America Lipid-lowering Agent Sales by Type (2021-2026) & (k units) Table 17. North America Lipid-lowering Agent Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Lipid-lowering Agent Sales by Type (2021-2026) & (k units) Table 19. Europe Lipid-lowering Agent Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Lipid-lowering Agent Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Lipid-lowering Agent Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Lipid-lowering Agent Sales by Type (2021-2026) & (k units) Table 23. Latin America Lipid-lowering Agent Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Lipid-lowering Agent Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Lipid-lowering Agent Sales by Type (2021-2026) & (US$ Million) Table 26. Lipid-lowering Agent Industry Trends Table 27. Lipid-lowering Agent Industry Drivers Table 28. Lipid-lowering Agent Industry Opportunities and Challenges Table 29. Lipid-lowering Agent Industry Restraints Table 30. Global Lipid-lowering Agent Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Lipid-lowering Agent Revenue Market Share by Company (2021-2026) Table 32. Global Lipid-lowering Agent Sales by Company (2021-2026) & (k units) Table 33. Global Lipid-lowering Agent Sales Share by Company (2021-2026) Table 34. Global Lipid-lowering Agent Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Lipid-lowering Agent Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Lipid-lowering Agent Major Company Production Sites and Headquarters Table 37. Global Lipid-lowering Agent Company, Product Type & Application Table 38. Global Lipid-lowering Agent Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Lipid-lowering Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Lipid-lowering Agent Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Lipid-lowering Agent Sales by Region (2021-2026) & (k units) Table 43. Global Lipid-lowering Agent Sales Market Share in Volume by Region (2021-2026) Table 44. Global Lipid-lowering Agent Sales by Region (2021-2026) & (US$ Million) Table 45. Global Lipid-lowering Agent Sales Market Share in Value by Region (2021-2026) Table 46. Global Lipid-lowering Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Lipid-lowering Agent Sales by Region (2027-2032) & (k units) Table 48. Global Lipid-lowering Agent Sales Market Share in Volume by Region (2027-2032) Table 49. Global Lipid-lowering Agent Sales by Region (2027-2032) & (US$ Million) Table 50. Global Lipid-lowering Agent Sales Market Share in Value by Region (2027-2032) Table 51. Global Lipid-lowering Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Lipid-lowering Agent Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Lipid-lowering Agent Sales by Application (2021-2026) & (k units) Table 54. Global Lipid-lowering Agent Sales Market Share in Volume by Application (2021-2026) Table 55. Global Lipid-lowering Agent Sales by Application (2021-2026) & (US$ Million) Table 56. Global Lipid-lowering Agent Sales Market Share in Value by Application (2021-2026) Table 57. Global Lipid-lowering Agent Price by Application (2021-2026) & (US$/unit) Table 58. Global Lipid-lowering Agent Sales by Application (2027-2032) & (k units) Table 59. Global Lipid-lowering Agent Sales Market Share in Volume by Application (2027-2032) Table 60. Global Lipid-lowering Agent Sales by Application (2027-2032) & (US$ Million) Table 61. Global Lipid-lowering Agent Sales Market Share in Value by Application (2027-2032) Table 62. Global Lipid-lowering Agent Price by Application (2027-2032) & (US$/unit) Table 63. North America Lipid-lowering Agent Sales by Application (2021-2026) & (k units) Table 64. North America Lipid-lowering Agent Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Lipid-lowering Agent Sales by Application (2021-2026) & (k units) Table 66. Europe Lipid-lowering Agent Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Lipid-lowering Agent Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Lipid-lowering Agent Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Lipid-lowering Agent Sales by Application (2021-2026) & (k units) Table 70. Latin America Lipid-lowering Agent Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Lipid-lowering Agent Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Lipid-lowering Agent Sales by Application (2021-2026) & (US$ Million) Table 73. Abbott Company Information Table 74. Abbott Business Overview Table 75. Abbott Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Abbott Lipid-lowering Agent Product Portfolio Table 77. Abbott Recent Development Table 78. Teva Company Information Table 79. Teva Business Overview Table 80. Teva Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Teva Lipid-lowering Agent Product Portfolio Table 82. Teva Recent Development Table 83. SUN Pharma Company Information Table 84. SUN Pharma Business Overview Table 85. SUN Pharma Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. SUN Pharma Lipid-lowering Agent Product Portfolio Table 87. SUN Pharma Recent Development Table 88. Novartis Company Information Table 89. Novartis Business Overview Table 90. Novartis Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Novartis Lipid-lowering Agent Product Portfolio Table 92. Novartis Recent Development Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Merck Lipid-lowering Agent Product Portfolio Table 97. Merck Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Pfizer Lipid-lowering Agent Product Portfolio Table 102. Pfizer Recent Development Table 103. GlaxoSmithKline Company Information Table 104. GlaxoSmithKline Business Overview Table 105. GlaxoSmithKline Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. GlaxoSmithKline Lipid-lowering Agent Product Portfolio Table 107. GlaxoSmithKline Recent Development Table 108. Amgen Company Information Table 109. Amgen Business Overview Table 110. Amgen Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Amgen Lipid-lowering Agent Product Portfolio Table 112. Amgen Recent Development Table 113. Abbvie Company Information Table 114. Abbvie Business Overview Table 115. Abbvie Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Abbvie Lipid-lowering Agent Product Portfolio Table 117. Abbvie Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. AstraZeneca Lipid-lowering Agent Product Portfolio Table 122. AstraZeneca Recent Development Table 123. Torrent Pharmaceuticals Company Information Table 124. Torrent Pharmaceuticals Business Overview Table 125. Torrent Pharmaceuticals Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Torrent Pharmaceuticals Lipid-lowering Agent Product Portfolio Table 127. Torrent Pharmaceuticals Recent Development Table 128. JX Pharmaceuticals Company Information Table 129. JX Pharmaceuticals Business Overview Table 130. JX Pharmaceuticals Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. JX Pharmaceuticals Lipid-lowering Agent Product Portfolio Table 132. JX Pharmaceuticals Recent Development Table 133. HanAll BioPharma Company Information Table 134. HanAll BioPharma Business Overview Table 135. HanAll BioPharma Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. HanAll BioPharma Lipid-lowering Agent Product Portfolio Table 137. HanAll BioPharma Recent Development Table 138. Cerenis Therapeutics Company Information Table 139. Cerenis Therapeutics Business Overview Table 140. Cerenis Therapeutics Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Cerenis Therapeutics Lipid-lowering Agent Product Portfolio Table 142. Cerenis Therapeutics Recent Development Table 143. Aurobindo Pharma Company Information Table 144. Aurobindo Pharma Business Overview Table 145. Aurobindo Pharma Lipid-lowering Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Aurobindo Pharma Lipid-lowering Agent Product Portfolio Table 147. Aurobindo Pharma Recent Development Table 148. North America Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 149. North America Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 150. North America Lipid-lowering Agent Sales Market Share by Country (2021-2026) Table 151. North America Lipid-lowering Agent Sales Forecast by Country (2027-2032) & (k units) Table 152. North America Lipid-lowering Agent Sales Market Share Forecast by Country (2027-2032) Table 153. North America Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Lipid-lowering Agent Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Lipid-lowering Agent Market Share by Country (2021-2026) Table 156. North America Lipid-lowering Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Lipid-lowering Agent Market Share Forecast by Country (2027-2032) Table 158. Europe Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 159. Europe Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 160. Europe Lipid-lowering Agent Sales Market Share by Country (2021-2026) Table 161. Europe Lipid-lowering Agent Sales Forecast by Country (2027-2032) & (k units) Table 162. Europe Lipid-lowering Agent Sales Market Share Forecast by Country (2027-2032) Table 163. Europe Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe Lipid-lowering Agent Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe Lipid-lowering Agent Market Share by Country (2021-2026) Table 166. Europe Lipid-lowering Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe Lipid-lowering Agent Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 170. Asia-Pacific Lipid-lowering Agent Sales Market Share by Country (2021-2026) Table 171. Asia-Pacific Lipid-lowering Agent Sales Forecast by Country (2027-2032) & (k units) Table 172. Asia-Pacific Lipid-lowering Agent Sales Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Lipid-lowering Agent Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific Lipid-lowering Agent Market Share by Country (2021-2026) Table 176. Asia-Pacific Lipid-lowering Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific Lipid-lowering Agent Market Share Forecast by Country (2027-2032) Table 178. Latin America Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 179. Latin America Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 180. Latin America Lipid-lowering Agent Sales Market Share by Country (2021-2026) Table 181. Latin America Lipid-lowering Agent Sales Forecast by Country (2027-2032) & (k units) Table 182. Latin America Lipid-lowering Agent Sales Market Share Forecast by Country (2027-2032) Table 183. Latin America Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Latin America Lipid-lowering Agent Market Size by Country (2021-2026) & (US$ Million) Table 185. Latin America Lipid-lowering Agent Market Share by Country (2021-2026) Table 186. Latin America Lipid-lowering Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Latin America Lipid-lowering Agent Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa Lipid-lowering Agent Sales by Country (2021-2026) & (k units) Table 190. Middle East and Africa Lipid-lowering Agent Sales Market Share by Country (2021-2026) Table 191. Middle East and Africa Lipid-lowering Agent Sales Forecast by Country (2027-2032) & (k units) Table 192. Middle East and Africa Lipid-lowering Agent Sales Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Lipid-lowering Agent Market Size by Country (2021-2026) & (US$ Million) Table 195. Middle East and Africa Lipid-lowering Agent Market Share by Country (2021-2026) Table 196. Middle East and Africa Lipid-lowering Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Lipid-lowering Agent Market Share Forecast by Country (2027-2032) Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. Lipid-lowering Agent Distributors List Table 201. Lipid-lowering Agent Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Lipid-lowering Agent Image Figure 2. Global Lipid-lowering Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lipid-lowering Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Lipid-lowering Agent Sales (2021-2032) & (k units) Figure 5. Acipimox Image Figure 6. Global Acipimox Sales YoY Growth (2021-2032) & (k units) Figure 7. Fibrates Image Figure 8. Global Fibrates Sales YoY Growth (2021-2032) & (k units) Figure 9. Niaci Image Figure 10. Global Niaci Sales YoY Growth (2021-2032) & (k units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Lipid-lowering Agent Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Lipid-lowering Agent Market Share by Type 2025 VS 2032 Figure 15. North America Lipid-lowering Agent Sales Market Share in Volume by Type in 2025 Figure 16. North America Lipid-lowering Agent Sales Market Share in Value by Type in 2025 Figure 17. Europe Lipid-lowering Agent Sales Market Share in Volume by Type in 2025 Figure 18. Europe Lipid-lowering Agent Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Lipid-lowering Agent Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Lipid-lowering Agent Sales Market Share in Value by Type in 2025 Figure 21. Latin America Lipid-lowering Agent Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Lipid-lowering Agent Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Lipid-lowering Agent Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Lipid-lowering Agent Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Lipid-lowering Agent Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospitals Image Figure 28. Global Hospitals Sales YoY Growth (2021-2032) & (k units) Figure 29. Clinics Image Figure 30. Global Clinics Sales YoY Growth (2021-2032) & (k units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Lipid-lowering Agent Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Lipid-lowering Agent Market Share by Application 2025 VS 2032 Figure 35. North America Lipid-lowering Agent Sales Market Share in Volume by Application in 2025 Figure 36. North America Lipid-lowering Agent Sales Market Share in Value by Application in 2025 Figure 37. Europe Lipid-lowering Agent Sales Market Share in Volume by Application in 2025 Figure 38. Europe Lipid-lowering Agent Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Lipid-lowering Agent Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Lipid-lowering Agent Sales Market Share in Value by Application in 2025 Figure 41. Latin America Lipid-lowering Agent Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Lipid-lowering Agent Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Lipid-lowering Agent Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Lipid-lowering Agent Sales Market Share in Value by Application in 2025 Figure 45. North America Lipid-lowering Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Lipid-lowering Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Lipid-lowering Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Lipid-lowering Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Lipid-lowering Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Lipid-lowering Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Lipid-lowering Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Lipid-lowering Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Lipid-lowering Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Lipid-lowering Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Lipid-lowering Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Lipid-lowering Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Lipid-lowering Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Lipid-lowering Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Lipid-lowering Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Lipid-lowering Agent Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Lipid-lowering Agent Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Acipimox
  • Fibrates
  • Niaci
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Abbott
  • Teva
  • SUN Pharma
  • Novartis
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Amgen
  • Abbvie
  • AstraZeneca
  • Torrent Pharmaceuticals
  • JX Pharmaceuticals
  • HanAll BioPharma
  • Cerenis Therapeutics
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Lipid-lowering Agent Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Lipid-lowering Agent Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Lipid-lowering Agent Market by Type
  6. 1.3.1 Acipimox
  7. 1.3.2 Fibrates
  8. 1.3.3 Niaci
  9. 1.3.4 Others
  10. 1.4 Global Lipid-lowering Agent Market Size by Type
  11. 1.4.1 Global Lipid-lowering Agent Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Lipid-lowering Agent Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Lipid-lowering Agent Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Lipid-lowering Agent Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Lipid-lowering Agent Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Lipid-lowering Agent Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Lipid-lowering Agent Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Lipid-lowering Agent Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Lipid-lowering Agent Industry Trends
  2. 2.2 Lipid-lowering Agent Industry Drivers
  3. 2.3 Lipid-lowering Agent Industry Opportunities and Challenges
  4. 2.4 Lipid-lowering Agent Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Lipid-lowering Agent Revenue (2021-2026)
  2. 3.2 Global Top Players by Lipid-lowering Agent Sales (2021-2026)
  3. 3.3 Global Top Players by Lipid-lowering Agent Price (2021-2026)
  4. 3.4 Global Lipid-lowering Agent Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Lipid-lowering Agent Major Company Production Sites & Headquarters
  6. 3.6 Global Lipid-lowering Agent Company, Product Type & Application
  7. 3.7 Global Lipid-lowering Agent Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Lipid-lowering Agent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Lipid-lowering Agent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Lipid-lowering Agent Tier 1, Tier 2, and Tier 3
4 Lipid-lowering Agent Regional Status and Outlook
  1. 4.1 Global Lipid-lowering Agent Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Lipid-lowering Agent Historic Market Size by Region
  3. 4.2.1 Global Lipid-lowering Agent Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Lipid-lowering Agent Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Lipid-lowering Agent Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Lipid-lowering Agent Forecasted Market Size by Region
  7. 4.3.1 Global Lipid-lowering Agent Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Lipid-lowering Agent Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Lipid-lowering Agent Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Lipid-lowering Agent by Application
  1. 5.1 Lipid-lowering Agent Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Lipid-lowering Agent Market Size by Application
  6. 5.2.1 Global Lipid-lowering Agent Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Lipid-lowering Agent Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Lipid-lowering Agent Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Lipid-lowering Agent Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Lipid-lowering Agent Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Lipid-lowering Agent Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Lipid-lowering Agent Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Lipid-lowering Agent Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Abbott
  2. 6.1.1 Abbott Company Information
  3. 6.1.2 Abbott Business Overview
  4. 6.1.3 Abbott Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Abbott Lipid-lowering Agent Product Portfolio
  6. 6.1.5 Abbott Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Teva Lipid-lowering Agent Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 SUN Pharma
  14. 6.3.1 SUN Pharma Company Information
  15. 6.3.2 SUN Pharma Business Overview
  16. 6.3.3 SUN Pharma Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 SUN Pharma Lipid-lowering Agent Product Portfolio
  18. 6.3.5 SUN Pharma Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Lipid-lowering Agent Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck Lipid-lowering Agent Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Lipid-lowering Agent Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 GlaxoSmithKline
  38. 6.7.1 GlaxoSmithKline Company Information
  39. 6.7.2 GlaxoSmithKline Business Overview
  40. 6.7.3 GlaxoSmithKline Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 GlaxoSmithKline Lipid-lowering Agent Product Portfolio
  42. 6.7.5 GlaxoSmithKline Recent Developments
  43. 6.8 Amgen
  44. 6.8.1 Amgen Company Information
  45. 6.8.2 Amgen Business Overview
  46. 6.8.3 Amgen Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Amgen Lipid-lowering Agent Product Portfolio
  48. 6.8.5 Amgen Recent Developments
  49. 6.9 Abbvie
  50. 6.9.1 Abbvie Company Information
  51. 6.9.2 Abbvie Business Overview
  52. 6.9.3 Abbvie Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Abbvie Lipid-lowering Agent Product Portfolio
  54. 6.9.5 Abbvie Recent Developments
  55. 6.10 AstraZeneca
  56. 6.10.1 AstraZeneca Company Information
  57. 6.10.2 AstraZeneca Business Overview
  58. 6.10.3 AstraZeneca Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AstraZeneca Lipid-lowering Agent Product Portfolio
  60. 6.10.5 AstraZeneca Recent Developments
  61. 6.11 Torrent Pharmaceuticals
  62. 6.11.1 Torrent Pharmaceuticals Company Information
  63. 6.11.2 Torrent Pharmaceuticals Business Overview
  64. 6.11.3 Torrent Pharmaceuticals Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Torrent Pharmaceuticals Lipid-lowering Agent Product Portfolio
  66. 6.11.5 Torrent Pharmaceuticals Recent Developments
  67. 6.12 JX Pharmaceuticals
  68. 6.12.1 JX Pharmaceuticals Company Information
  69. 6.12.2 JX Pharmaceuticals Business Overview
  70. 6.12.3 JX Pharmaceuticals Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 JX Pharmaceuticals Lipid-lowering Agent Product Portfolio
  72. 6.12.5 JX Pharmaceuticals Recent Developments
  73. 6.13 HanAll BioPharma
  74. 6.13.1 HanAll BioPharma Company Information
  75. 6.13.2 HanAll BioPharma Business Overview
  76. 6.13.3 HanAll BioPharma Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 HanAll BioPharma Lipid-lowering Agent Product Portfolio
  78. 6.13.5 HanAll BioPharma Recent Developments
  79. 6.14 Cerenis Therapeutics
  80. 6.14.1 Cerenis Therapeutics Company Information
  81. 6.14.2 Cerenis Therapeutics Business Overview
  82. 6.14.3 Cerenis Therapeutics Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Cerenis Therapeutics Lipid-lowering Agent Product Portfolio
  84. 6.14.5 Cerenis Therapeutics Recent Developments
  85. 6.15 Aurobindo Pharma
  86. 6.15.1 Aurobindo Pharma Company Information
  87. 6.15.2 Aurobindo Pharma Business Overview
  88. 6.15.3 Aurobindo Pharma Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Aurobindo Pharma Lipid-lowering Agent Product Portfolio
  90. 6.15.5 Aurobindo Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Lipid-lowering Agent Sales by Country
  2. 7.1.1 North America Lipid-lowering Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Lipid-lowering Agent Sales by Country (2021-2026)
  4. 7.1.3 North America Lipid-lowering Agent Sales Forecast by Country (2027-2032)
  5. 7.2 North America Lipid-lowering Agent Market Size by Country
  6. 7.2.1 North America Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Lipid-lowering Agent Market Size by Country (2021-2026)
  8. 7.2.3 North America Lipid-lowering Agent Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Lipid-lowering Agent Sales by Country
  2. 8.1.1 Europe Lipid-lowering Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Lipid-lowering Agent Sales by Country (2021-2026)
  4. 8.1.3 Europe Lipid-lowering Agent Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Lipid-lowering Agent Market Size by Country
  6. 8.2.1 Europe Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Lipid-lowering Agent Market Size by Country (2021-2026)
  8. 8.2.3 Europe Lipid-lowering Agent Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Lipid-lowering Agent Sales by Country
  2. 9.1.1 Asia-Pacific Lipid-lowering Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Lipid-lowering Agent Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Lipid-lowering Agent Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Lipid-lowering Agent Market Size by Country
  6. 9.2.1 Asia-Pacific Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Lipid-lowering Agent Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Lipid-lowering Agent Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Lipid-lowering Agent Sales by Country
  2. 10.1.1 South America Lipid-lowering Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Lipid-lowering Agent Sales by Country (2021-2026)
  4. 10.1.3 South America Lipid-lowering Agent Sales Forecast by Country (2027-2032)
  5. 10.2 South America Lipid-lowering Agent Market Size by Country
  6. 10.2.1 South America Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Lipid-lowering Agent Market Size by Country (2021-2026)
  8. 10.2.3 South America Lipid-lowering Agent Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Lipid-lowering Agent Sales by Country
  2. 11.1.1 Middle East and Africa Lipid-lowering Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Lipid-lowering Agent Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Lipid-lowering Agent Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Lipid-lowering Agent Market Size by Country
  6. 11.2.1 Middle East and Africa Lipid-lowering Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Lipid-lowering Agent Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Lipid-lowering Agent Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Lipid-lowering Agent Value Chain Analysis
  2. 12.1.1 Lipid-lowering Agent Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Lipid-lowering Agent Production Mode & Process
  7. 12.2 Lipid-lowering Agent Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Lipid-lowering Agent Distributors
  10. 12.2.3 Lipid-lowering Agent Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst